1
|
Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Vitt D, Kohlhof H, Slizgi J, Ondrus M, Sciacca V, Muehler AR. Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial. Neurol Neuroimmunol Neuroinflamm 2024; 11:e200208. [PMID: 38662979 PMCID: PMC11087024 DOI: 10.1212/nxi.0000000000200208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Accepted: 01/19/2024] [Indexed: 05/12/2024]
Abstract
BACKGROUND AND OBJECTIVES Vidofludimus calcium suppressed MRI disease activity compared with placebo in patients with relapsing-remitting multiple sclerosis (RRMS) in the first cohort of the phase 2 EMPhASIS study. Because 30 mg and 45 mg showed comparable activity on multiple end points, the study enrolled an additional low-dose cohort to further investigate a dose-response relationship. METHODS In a randomized, placebo-controlled, phase 2 trial, patients with RRMS, aged 18-55 years, and with ≥2 relapses in the last 2 years or ≥1 relapse in the last year, and ≥1 gadolinium-enhancing brain lesion in the last 6 months. Patients were randomly assigned (1:1:1) vidofludimus calcium (30 or 45 mg) or placebo in cohort 1 and vidofludimus calcium (10 mg) or placebo (4:1) in cohort 2 for 24 weeks. The primary end point was the cumulative number of combined unique active (CUA) lesions at week 24. Secondary end points were clinical outcomes and safety. RESULTS Across cohorts 1 and 2, 268 patients were randomized to placebo (n = 81), 10 mg (n = 47) vidofludimus calcium, 30 mg (n = 71) vidofludimus calcium, or 45 mg (n = 69) vidofludimus calcium. The mean cumulative CUA lesions over 24 weeks was 5.8 (95% CI 4.1-8.2) for placebo, 5.9 (95% CI 3.9-9.0) for 10 mg treatment group, 1.4 (95% CI 0.9-2.1) for 30 mg treatment group, and 1.7 (95% CI 1.1-2.5) for 45 mg treatment group. Serum neurofilament light chain decreased in a dose-dependent manner. The number of patients with confirmed disability worsening after 24 weeks was 3 (3.7%) patients receiving placebo and 3 (1.6%) patients receiving any dose of vidofludimus calcium. Treatment-emergent adverse events occurred in 35 (43%) placebo patients compared with 11 (23%) and 71 (37%) patients in the 10 mg or any dose of vidofludimus calcium groups, respectively. The incidence of liver enzyme elevations and infections were similar between placebo and any dose of vidofludimus calcium. No new safety signals were observed. DISCUSSION Compared with placebo, vidofludimus calcium suppressed the development of new brain lesions with daily doses of 30 mg and 45 mg, but not 10 mg, establishing the lowest efficacious dose is 30 mg. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that among adults with active RRMS and ≥1 Gd+ brain lesion in the past 6 months, the cumulative number of active lesions decreased with vidofludimus calcium. TRIAL REGISTRATION INFORMATION ClinicalTrials.gov (NCT03846219) and EudraCT (2018-001896-19).
Collapse
Affiliation(s)
- Robert J Fox
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Heinz Wiendl
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Christian Wolf
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Nicola De Stefano
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Johann Sellner
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Viktoriia Gryb
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Konrad Rejdak
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Plamen S Bozhinov
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Daniel Vitt
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Hella Kohlhof
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Jason Slizgi
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Matej Ondrus
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Valentina Sciacca
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| | - Andreas R Muehler
- From the Mellen Center for Multiple Sclerosis (R.J.F.), Cleveland Clinic, OH; Department of Neurology with Institute of Translational Neurology (H.W.), University of Münster, Germany; Lycalis sprl (C.W.), Brussels, Belgium; Department of Medicine (N.D.S.), Surgery and Neuroscience, University of Siena, Italy; Department of Neurology (J. Sellner), Landesklinikum Mistelbach-Gänserndorf, Austria; Regional Clinical Hospital Department of Vascular Neurology (V.G.), Ivano-Frankivsk, Ukraine; Department of Neurology (K.R.), Medical University of Lublin, Lublin, Poland; Medical University of Pleven (P.S.B.), Bulgaria; Immunic AG (D.V., H.K., M.O., V.S., A.R.M.), Gräfelfing, Germany; and independent consultant (J. Slizgi), Raleigh, NC
| |
Collapse
|
2
|
White JP, Schembri A, Prenn-Gologranc C, Ondrus M, Katina S, Novak P, Lim YY, Edgar C, Maruff P. Sensitivity of Individual and Composite Test Scores from the Cogstate Brief Battery to Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease. J Alzheimers Dis 2023; 96:1781-1799. [PMID: 38007647 DOI: 10.3233/jad-230352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2023]
Abstract
BACKGROUND The Cogstate Brief Battery (CBB) is a computerized cognitive test battery used commonly to identify cognitive deficits related to Alzheimer's disease (AD). However, AD and normative samples used to understand the sensitivity of the CBB to AD in the clinic have been limited, as have the outcome measures studied. OBJECTIVE This study investigated the sensitivity of CBB outcomes, including potential composite scores, to cognitive impairment in mild cognitive impairment (MCI) and dementia due to AD, in carefully selected samples. METHODS Samples consisted of 4,871 cognitively unimpaired adults and 184 adults who met clinical criteria for MCI (Clinical Dementia Rating (CDR) = 0.5) or dementia (CDR > 0.5) due to AD and CBB naive. Speed and accuracy measures from each test were examined, and theoretically- and statistically-derived composites were created. Sensitivity and specificity of classification of cognitive impairment were compared between outcomes. RESULTS Individual CBB measures of learning and working memory showed high discriminability for AD-related cognitive impairment for CDR 0.5 (AUCs ∼ 0.79-0.88), and CDR > 0.5 (AUCs ∼ 0.89-0.96) groups. Discrimination ability for theoretically derived CBB composite measures was high, particularly for the Learning and Working Memory (LWM) composite (CDR 0.5 AUC = 0.90, CDR > 0.5 AUC = 0.97). As expected, statistically optimized linear composite measures showed strong discrimination abilities albeit similar to the LWM composite. CONCLUSIONS In older adults, the CBB is effective for discriminating cognitive impairment due to MCI or AD-dementia from unimpaired cognition with the LWM composite providing the strongest sensitivity.
Collapse
Affiliation(s)
| | | | | | | | - Stanislav Katina
- AXON Neuroscience CRM Services SE, Bratislava, Slovakia
- Institute of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic
| | - Petr Novak
- AXON Neuroscience CRM Services SE, Bratislava, Slovakia
| | - Yen Ying Lim
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia
| | - Chris Edgar
- Cogstate Ltd, Melbourne, Victoria, Australia
| | - Paul Maruff
- Cogstate Ltd, Melbourne, Victoria, Australia
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
3
|
Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nat Aging 2021; 1:521-534. [PMID: 37117834 DOI: 10.1038/s43587-021-00070-2] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 04/28/2021] [Indexed: 04/30/2023]
Abstract
Alzheimer's disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter placebo-controlled trial of AADvac1, an active peptide vaccine designed to target pathological tau in AD (EudraCT 2015-000630-30). Eleven doses of AADvac1 were administered to patients with mild AD dementia at 40 μg per dose over the course of the trial. The primary objective was to evaluate the safety and tolerability of long-term AADvac1 treatment. The secondary objectives were to evaluate immunogenicity and efficacy of AADvac1 treatment in slowing cognitive and functional decline. A total of 196 patients were randomized 3:2 between AADvac1 and placebo. AADvac1 was safe and well tolerated (AADvac1 n = 117, placebo n = 79; serious adverse events observed in 17.1% of AADvac1-treated individuals and 24.1% of placebo-treated individuals; adverse events observed in 84.6% of AADvac1-treated individuals and 81.0% of placebo-treated individuals). The vaccine induced high levels of IgG antibodies. No significant effects were found in cognitive and functional tests on the whole study sample (Clinical Dementia Rating-Sum of the Boxes scale adjusted mean point difference -0.360 (95% CI -1.306, 0.589)), custom cognitive battery adjusted mean z-score difference of 0.0008 (95% CI -0.169, 0.172). We also present results from exploratory and post hoc analyses looking at relevant biomarkers and clinical outcomes in specific subgroups. Our results show that AADvac1 is safe and immunogenic, but larger stratified studies are needed to better evaluate its potential clinical efficacy and impact on disease biomarkers.
Collapse
Affiliation(s)
- Petr Novak
- AXON Neuroscience CRM Services SE, Bratislava, Slovakia.
| | | | | | - Reinhold Schmidt
- Clinical Division of Neurogeriatrics, Department of Neurology, Medical University Graz, Graz, Austria
| | - Philip Scheltens
- Alzheimer Center, Amsterdam University Medical Centers, Amsterdam, the Netherlands
| | | | - Stefan Ropele
- Clinical Division of General Neurology, Department of Neurology, Medical University Graz, Graz, Austria
| | | | - Milica Kramberger
- Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia
| | | | | | - Jozef Hanes
- AXON Neuroscience R&D Services SE, Bratislava, Slovakia
| | - Eva Stevens
- AXON Neuroscience R&D Services SE, Bratislava, Slovakia
| | - Andrej Kovac
- AXON Neuroscience R&D Services SE, Bratislava, Slovakia
| | - Stanislav Sutovsky
- 1st Department of Neurology, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
| | | | - Peter Koson
- AXON Neuroscience CRM Services SE, Bratislava, Slovakia
| | - Michal Prcina
- AXON Neuroscience R&D Services SE, Bratislava, Slovakia
| | | | - Martin Cente
- AXON Neuroscience R&D Services SE, Bratislava, Slovakia
| | - Tomas Hromadka
- Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia
| | | | | | - Maria Samcova
- AXON Neuroscience CRM Services SE, Bratislava, Slovakia
| | | | - Roman Sivak
- AXON Neuroscience CRM Services SE, Bratislava, Slovakia
| | - Lutz Froelich
- Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, Medical Faculty Mannheim University of Heidelberg, Heidelberg, Germany
| | | | - Martin Rakusa
- Department of Neurological Diseases, University Medical Centre Maribor, Maribor, Slovenia
| | - John Harrison
- Alzheimer Center, Amsterdam University Medical Centers, Amsterdam, the Netherlands
| | - Jakub Hort
- Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
| | - Markus Otto
- Department of Neurology, Ulm University Hospital, Ulm, Germany
| | - Duygu Tosun
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
| | - Matej Ondrus
- AXON Neuroscience CRM Services SE, Bratislava, Slovakia
| | - Bengt Winblad
- Division of Neurogeriatrics, Center for Alzheimer Research, Karolinska Institutet, Solna, Sweden
- Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden
| | | | - Norbert Zilka
- AXON Neuroscience R&D Services SE, Bratislava, Slovakia
| |
Collapse
|
4
|
Novak P, Zilka N, Zilkova M, Kovacech B, Skrabana R, Ondrus M, Fialova L, Kontsekova E, Otto M, Novak M. AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development. J Prev Alzheimers Dis 2020; 6:63-69. [PMID: 30569088 DOI: 10.14283/jpad.2018.45] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Neurofibrillary tau protein pathology is closely associated with the progression and phenotype of cognitive decline in Alzheimer's disease and other tauopathies, and a high-priority target for disease-modifying therapies. Herein, we provide an overview of the development of AADvac1, an active immunotherapy against tau pathology, and tau epitopes that are potential targets for immunotherapy. The vaccine leads to the production of antibodies that target conformational epitopes in the microtubule-binding region of tau, with the aim to prevent tau aggregation and spreading of pathology, and promote tau clearance. The therapeutic potential of the vaccine was evaluated in transgenic rats and mice expressing truncated, non mutant tau protein, which faithfully replicate of human tau pathology. Treatment with AADvac1 resulted in reduction of neurofibrillary pathology and insoluble tau in their brains, and amelioration of their deleterious phenotype. The vaccine was highly immunogenic in humans, inducing production of IgG antibodies against the tau peptide in 29/30 treated elderly patients with mild-to-moderate Alzheimer's. These antibodies were able to recognise insoluble tau proteins in Alzheimer patients' brains. Treatment with AADvac1 proved to be remarkably safe, with injection site reactions being the only adverse event tied to treatment. AADvac1 is currently being investigated in a phase 2 study in Alzheimer's disease, and a phase 1 study in non-fluent primary progressive aphasia, a neurodegenerative disorder with a high tau pathology component.
Collapse
Affiliation(s)
- P Novak
- P. Novak, Axon Neuroscience CRM Services SE, Slovakia, +421911187237,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst) 2019; 11:301-309. [PMID: 30984816 PMCID: PMC6446052 DOI: 10.1016/j.dadm.2019.01.011] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
INTRODUCTION Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders. METHODS To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies. RESULTS As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression). DISCUSSION We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.
Collapse
Affiliation(s)
- Thilo van Eimeren
- Multimodal Neuroimaging, Department of Nuclear Medicine, Medical Faculty and University Hospital, University of Cologne, Cologne, Germany
- German Centre for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany
| | - Angelo Antonini
- Department of Neuroscience, University of Padua, Padua, Italy
| | - Daniela Berg
- Department of Neurology, UKSH, Campus Kiel, Christian-Albrechts-University, Kiel, Germany
| | - Nico Bohnen
- Division of Nuclear Medicine, Department of Radiology, University of Michigan, and VAMC, Ann Arbor, MI, USA
- Department of Neurology, University of Michigan, Ann Arbor, MI, USA
- VAMC, Ann Arbor, MI, USA
| | - Roberto Ceravolo
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Alexander Drzezga
- Multimodal Neuroimaging, Department of Nuclear Medicine, Medical Faculty and University Hospital, University of Cologne, Cologne, Germany
- German Centre for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany
- Forschungszentrum Jülich, INM-2, Jülich, Germany
| | - Günter U. Höglinger
- German Centre for Neurodegenerative Diseases (DZNE), and Technical University Munich, Department of Neurology, Munich, Germany
| | - Makoto Higuchi
- National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Stephane Lehericy
- Institut du Cerveau et de la Moelle épinière – ICM, Centre de NeuroImagerie de Recherche – CENIR, ICM Team “Movement Investigations and Therapeutics”, Sorbonne Universités, Inserm U1127, CNRS UMR, Paris, France
| | - Simon Lewis
- Brain & Mind Centre, Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - Oury Monchi
- Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
- Department of Radiology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
| | - Peter Nestor
- Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia
- Mater Hospital, South Brisbane, QLD, Australia
| | - Matej Ondrus
- AXON Neuroscience CRM Services SE, Bratislava, Slovak Republic
| | - Nicola Pavese
- Newcastle Magnetic Resonance Centre & Positron Emission Tomography Centre, Newcastle University, Newcastle upon Tyne, United Kingdom
| | - María Cecilia Peralta
- Center for Medical Education and Clinical Research, Section of Neurology, Buenos Aires, Argentina
| | - Paola Piccini
- Department of Medicine, Imperial College London, London, United Kingdom
| | - José Ángel Pineda-Pardo
- hmCINAC, University Hospital HM Puerta del Sur, CEU-San Pablo University, Móstoles, Madrid, Spain
| | - Irena Rektorová
- First Department of Neurology – Faculty of Medicine and CEITEC MU, Masaryk University, Brno, Czech Republic
| | | | - Axel Rominger
- Department of Nuclear Medicine, Inselspital, Universitätsspital Bern, Bern, Switzerland
| | - Klaus Seppi
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - A. Jon Stoessl
- Pacific Parkinson’s Research Centre, University of British Columbia, Vancouver, Canada
| | - Alessandro Tessitore
- Department of Medical, Surgery, Neurological, Metabolic and Aging Sciences, University of Campania, “L. Vanvitelli”, Caserta CE, Italy
| | - Stephane Thobois
- Université de Lyon, Université Claude Bernard Lyon 1, Faculté de Medecine Lyon Sud Charles Merieux, Lyon, France
- Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Neurologie C, Lyon, France
- CNRS, Institut des Sciences Cognitives, Bron, France
| | - Valtteri Kaasinen
- Department of Neurology, University of Turku, Turku, Finland
- Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland
| | - Gregor Wenning
- Division of Clinical Neurology, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Hartwig R. Siebner
- Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
| | - Antonio P. Strafella
- E.J. Safra Parkinson Disease Program, Toronto Western Hospital & Krembil Research Institute, UHN, Toronto, Ontario, Canada
- Research Imaging Centre, Campbell Family Mental Health Research Institute, CAMH, Toronto, Ontario, Canada
- University of Toronto, Toronto, Ontario, Canada
| | - James B. Rowe
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|
6
|
Novak P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Zilka N, Winblad B, Novak M. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther 2018; 10:108. [PMID: 30355322 PMCID: PMC6201586 DOI: 10.1186/s13195-018-0436-1] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Accepted: 09/26/2018] [Indexed: 11/30/2022]
Abstract
Background Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer’s disease and non-Alzheimer’s tauopathies. Targeting pathological tau proteins via immunotherapy is a promising strategy for disease-modifying treatment of Alzheimer’s disease. Previously, we reported a 24-week phase 1 trial on the active vaccine AADvac1 against pathological tau protein; here, we present the results of a further 72 weeks of follow-up on those patients. Methods We did a phase 1, 72-week, open-label study of AADvac1 in patients with mild to moderate Alzheimer’s disease who had completed the preceding phase 1 study. Patients who were previously treated with six doses of AADvac1 at monthly intervals received two booster doses at 24-week intervals. Patients who were previously treated with only three doses received another three doses at monthly intervals, and subsequently two boosters at 24-week intervals. The primary objective was the assessment of long-term safety of AADvac1 treatment. Secondary objectives included assessment of antibody titres, antibody isotype profile, capacity of the antibodies to bind to AD tau and AADvac1, development of titres of AADvac1-induced antibodies over time, and effect of booster doses; cognitive assessment via 11-item Alzheimer’s Disease Assessment Scale cognitive assessment (ADAS-Cog), Category Fluency Test and Controlled Oral Word Association Test; assessment of brain atrophy via magnetic resonance imaging (MRI) volumetry; and assessment of lymphocyte populations via flow cytometry. Results The study was conducted between 18 March 2014 and 10 August 2016. Twenty-six patients who completed the previous study were enrolled. Five patients withdrew because of adverse events. One patient was withdrawn owing to noncompliance. The most common adverse events were injection site reactions (reported in 13 [50%] of vaccinated patients). No cases of meningoencephalitis or vasogenic oedema were observed. New micro-haemorrhages were observed only in one ApoE4 homozygote. All responders retained an immunoglobulin G (IgG) antibody response against the tau peptide component of AADvac1 over 6 months without administration, with titres regressing to a median 15.8% of titres attained after the initial six-dose vaccination regimen. Booster doses restored previous IgG levels. Hippocampal atrophy rate was lower in patients with high IgG levels; a similar relationship was observed in cognitive assessment. Conclusions AADvac1 displayed a benign safety profile. The evolution of IgG titres over vaccination-free periods warrants a more frequent booster dose regimen. The tendency towards slower atrophy in MRI evaluation and less of a decline in cognitive assessment in patients with high titres is encouraging. Further trials are required to expand the safety database and to establish proof of clinical efficacy of AADvac1. Trial registration The studies are registered with the EU Clinical Trials Register and ClinicalTrials.gov: the preceding first-in-human study under EudraCT 2012-003916-29 and NCT01850238 (registered on 9 May 2013) and the follow-up study under EudraCT 2013-004499-36 and NCT02031198 (registered 9 Jan 2014), respectively. Electronic supplementary material The online version of this article (10.1186/s13195-018-0436-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Petr Novak
- Axon Neuroscience CRM Services SE, Dvorakovo nabrezie 11, 811 02, Bratislava, Slovakia.
| | - Reinhold Schmidt
- Clinical Division of Neurogeriatrics and Division of General Neurology, Department of Neurology, Medical University Graz, Auenbruggerplatz 2, 8036, Graz, Austria
| | - Eva Kontsekova
- Axon Neuroscience R&D Services SE, Dvorakovo nabrezie 10, 811 02, Bratislava, Slovakia
| | - Branislav Kovacech
- Axon Neuroscience R&D Services SE, Dvorakovo nabrezie 10, 811 02, Bratislava, Slovakia
| | - Tomas Smolek
- Axon Neuroscience R&D Services SE, Dvorakovo nabrezie 10, 811 02, Bratislava, Slovakia
| | - Stanislav Katina
- Axon Neuroscience CRM Services SE, Dvorakovo nabrezie 11, 811 02, Bratislava, Slovakia
| | - Lubica Fialova
- Axon Neuroscience R&D Services SE, Dvorakovo nabrezie 10, 811 02, Bratislava, Slovakia
| | - Michal Prcina
- Axon Neuroscience R&D Services SE, Dvorakovo nabrezie 10, 811 02, Bratislava, Slovakia
| | - Vojtech Parrak
- Axon Neuroscience R&D Services SE, Dvorakovo nabrezie 10, 811 02, Bratislava, Slovakia
| | - Peter Dal-Bianco
- University Clinic of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Martin Brunner
- University Clinic of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Wolfgang Staffen
- University Clinic of Neurology, Christian-Doppler-Clinic, Ignaz-Harrer-Straße 79, 5020, Salzburg, Austria
| | - Michael Rainer
- Social and Medical Centre East, Danube Hospital, Karl Landsteiner Institute for Memory and Alzheimer Research, Langobardenstraße 122, 1220, Vienna, Austria
| | - Matej Ondrus
- Axon Neuroscience CRM Services SE, Dvorakovo nabrezie 11, 811 02, Bratislava, Slovakia
| | - Stefan Ropele
- Clinical Division of Neurogeriatrics and Division of General Neurology, Department of Neurology, Medical University Graz, Auenbruggerplatz 2, 8036, Graz, Austria
| | - Miroslav Smisek
- Axon Neuroscience CRM Services SE, Dvorakovo nabrezie 11, 811 02, Bratislava, Slovakia
| | - Roman Sivak
- Axon Neuroscience CRM Services SE, Dvorakovo nabrezie 11, 811 02, Bratislava, Slovakia
| | - Norbert Zilka
- Axon Neuroscience R&D Services SE, Dvorakovo nabrezie 10, 811 02, Bratislava, Slovakia
| | - Bengt Winblad
- Division of Neurogeriatrics, Department NVS Clinical Trial Unit, Karolinska Institute Alzheimer Disease Research Centre, Geriatric Clinic, Karolinska University Hospital, Hälsovägen 7, S-14157, Huddinge, Sweden
| | - Michal Novak
- Axon Neuroscience SE, 4, Arch. Makariou & Kalogreon, Nicolaides Sea View City, 5th floor, office 506, 6016, Larnaca, Cyprus
| |
Collapse
|
7
|
Qi X, Hatami S, White C, Himmat S, Aboelnazer N, Ondrus M, Wu Y, Kinnear A, Nagendran J, Freed D. Inflammation and Innate Immune Activation During Ex Vivo Heart Perfusion. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
8
|
Novak P, Zilka N, Kontsekova E, Ondrus M, Novak M. O4‐08‐01: Characterisation of the Antibody Response to AADVAC1: The First‐in‐Kind Active Vaccine Against Neurofibrillary TAU Pathology. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
|
10
|
Williams J, Ondrus M, Kitzinger M, Persson J, Popescu M, Valjakka R. EPA-0716 – An international study of the grid-hamd: has it fulfilled its promise. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78074-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|